Ahmet Murat Aydin, MD

Research Program: Cancer Therapeutics Faculty Rank: Assistant Professor Campus: University of Arkansas for Medical Sciences College: College of Medicine Department: Urology Faculty

Cancer Research Interest

• Disease Site Focus: GU
• Research Focus Area: Treatment, Health Disparities, Carcinogenesis, Diagnosis/ Prognosis, Prevention
• Type of Research: Translational, Clinical
• Research Keywords: Cancer Immunotherapy, Biomarker, Health Outcomes
• Research Interest Statement: My main research focus is characterization of immune suppressive mechanisms in genitourinary tumors, and development of novel dendritic cell-based cancer vaccines and T-cell based therapies against non-metastatic kidney and bladder cancers.

Contact Information

• Email Address: MAYDIN@UAMS.EDU
• Profiles Research Networking Software: View Profile

Open Clinical Trials

• “EA8134 InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)” (NCT02305654)

Recent Publications

• Aydin AM, Biben E, Yu A, [et al.]. Minimally Invasive Management of Inguinal Lymph Nodes in Penile Cancer: Recent Progress and Remaining Challenges. Cancers. 2024 16(17). PMID: 39272796. PMCID: PMC11394048.
• Jackson JC, Sanchez D, Johns AC, [et al., including Aydin AM]. Germ Cell Tumor of the Testis: Lethal Subtypes of a Curable Cancer. Journal of clinical medicine. 2024 13(12). PMID: 38929965. PMCID: PMC11205088.
• Biben E, Menon L, Gokden N, [et al., including Aydin AM]. Giant left pheochromocytoma with vascular anomalies and pelvic horseshoe kidney: a case report. BMC urology. 2023 23(1):204. PMID: 38066479. PMCID: PMC10704855.
• Tu SM, Chen JZ, Singh SR, [et al., including Aydin AM]. Stem Cell Theory of Cancer: Clinical Implications of Epigenomic versus Genomic Biomarkers in Cancer Care. Cancers. 2023 15(23). PMID: 38067237. PMCID: PMC10705798.
• Tu SM, Aydin AM, Maraboyina S, [et al.]. Stem Cell Origin of Cancer: Clinical Implications for Cancer Immunity and Immunotherapy. Cancers. 2023 15(22). PMID: 38001645. PMCID: PMC10670143.
• Tu SM, Aydin AM, Maraboyina S, [et al.]. Stem Cell Origin of Cancer: Implications of Oncogenesis Recapitulating Embryogenesis in Cancer Care. Cancers. 2023 15(9). PMID: 37173982. PMCID: PMC10177345.
• Aydin AM, Cheriyan SK, Reich R, [et al.]. Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer. Urologic oncology. 2022. PMID: 35811208.
• Aydin AM, Reich RR, Cao B, [et al.]. Clinical indications for necessary and discretionary hospital readmissions after radical cystectomy. Urologic oncology. 2021. PMID: 34629281. PMCID: PMC8960322.
• Chakiryan NH, Kimmel GJ, Kim Y, [et al., including Aydin AM]. Geospatial Cellular Distribution of Cancer-Associated Fibroblasts Significantly Impacts Clinical Outcomes in Metastatic Clear Cell Renal Cell Carcinoma. Cancers. 2021 13(15). PMID: 34359645. PMCID: PMC8345222.
• Hajiran A, Azizi M, Aydin AM, [et al.]. Retroperitoneal Lymph Node Dissection Versus Surveillance for Adult Early Stage Pure Testicular Teratoma: A Nationwide Analysis. Annals of surgical oncology. 2021 28(7):3648-3655. PMID: 33689081. PMCID: PMC9801512.
• Chakiryan NH, Hajiran A, Kim Y, [et al., including Aydin AM]. Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell Carcinoma. European urology focus. 2021. PMID: 33994165. PMCID: PMC11091541.
• Aydin AM, Hall M, Bunch BL, [et al.]. Expansion of tumor-infiltrating lymphocytes (TIL) from penile cancer patients. International immunopharmacology. 2021 94:107481. PMID: 33636562. PMCID: PMC8205103.
• Hajiran A, Chakiryan N, Aydin AM, [et al.]. Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response. Clinical and experimental immunology. 2021 204(1):96-106. PMID: 33346915. PMCID: PMC7944355.
• Hajiran A, Azizi M, Aydin AM, [et al.]. Reply By Authors. The Journal of urology. 2021 205(1):108. PMID: 33095102.
• Aydin AM, Bunch BL, Beatty M, [et al.]. The Factors Affecting Expansion of Reactive Tumor Infiltrating Lymphocytes (TIL) From Bladder Cancer and Potential Therapeutic Applications. Frontiers in immunology. 2021 12:628063. PMID: 33717150. PMCID: PMC7949015.
• Hajiran A, Azizi M, Aydin AM, [et al.]. Pathological and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed by Cystectomy with or without Neoadjuvant Chemotherapy. The Journal of urology. 2021 205(1):100-108. PMID: 32783489. PMCID: PMC7864376.
• Hajiran A, Zemp L, Aydin AM, [et al.]. Topical chemotherapy for penile carcinoma in situ: Contemporary outcomes and reported toxicity. Urologic oncology. 2021 39(1):72.e1-72.e5. PMID: 33036902.
• Chakiryan NH, Kimmel GJ, Kim Y, [et al., including Aydin AM]. Spatial clustering of CD68+ tumor associated macrophages with tumor cells is associated with worse overall survival in metastatic clear cell renal cell carcinoma. PloS one. 2021 16(4):e0245415. PMID: 33882057. PMCID: PMC8059840.
• Bunch BL, Morse J, Asby S, [et al., including Aydin AM]. Systemic and intravesical adoptive cell therapy of tumor-reactive T cells can decrease bladder tumor growth in vivo. Journal for immunotherapy of cancer. 2020 8(2). PMID: 33303579. PMCID: PMC7733200.
• Aydin AM, Chakiryan NH, Spiess PE. Will Dynamic Sentinel Lymph Node Biopsy Become the New International Standard for Evaluating High-risk Penile Cancer in Patients with Clinically Negative Lymph Nodes?. European urology. 2020 78(6):873-874. PMID: 33023773.
• Chertack N, Ghandour RA, Singla N, [et al., including Aydin AM]. Overcoming sociodemographic factors in the care of patients with testicular cancer at a safety net hospital. Cancer. 2020 126(19):4362-4370. PMID: 32776520.
• Aydin AM, Chahoud J, Adashek JJ, [et al.]. Understanding genomics and the immune environment of penile cancer to improve therapy. Nature reviews. Urology. 2020 17(10):555-570. PMID: 32812000.
• Aydin AM, Gage K, Dhillon J, [et al.]. Focal bipolar radiofrequency ablation for localized prostate cancer: Safety and feasibility. International journal of urology : official journal of the Japanese Urological Association. 2020 27(10):882-889. PMID: 32767444.
• Aydin AM, Baydar DE, Hazir B, [et al.]. Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy. World journal of urology. 2020 38(10):2537-2545. PMID: 31900581.
• Azizi M, Aydin AM, Hajiran A, [et al.]. Systematic Review and Meta-Analysis-Is there a Benefit in Using Neoadjuvant Systemic Chemotherapy for Locally Advanced Penile Squamous Cell Carcinoma?. The Journal of urology. 2020 203(6):1147-1155. PMID: 31928407.
• Azizi M, Aydin AM, Hajiran A, [et al.]. Reply by Authors. The Journal of urology. 2020 203(6):1155. PMID: 32176595.
• Cheriyan SK, Nicholson M, Aydin AM, [et al.]. Current management and management controversies in early- and intermediate-stage of nonseminoma germ cell tumors. Translational andrology and urology. 2020 9(Suppl 1):S45-S55. PMID: 32055485. PMCID: PMC6995850.
• Azizi M, Aydin AM, Cheriyan SK, [et al.]. Therapeutic strategies for uncommon testis cancer histologies: teratoma with malignant transformation and malignant testicular sex cord stromal tumors. Translational andrology and urology. 2020 9(Suppl 1):S91-S103. PMID: 32055490. PMCID: PMC6995843.
• Aydin AM, Zemp L, Cheriyan SK, [et al.]. Contemporary management of early stage testicular seminoma. Translational andrology and urology. 2020 9(Suppl 1):S36-S44. PMID: 32055484. PMCID: PMC6995845.